Sleep and neuropsychiatric illness

Sleep and neuropsychiatric illness are entwined. Disturbances of sleep are DSM-5 diagnostic features for major depressive disorder, generalized anxiety disorder, post-traumatic stress

disorder, and bipolar disorder, and are consistent features of psychoses and most neurodegenerative disorders. Pharmacologic or psychological treatment of these disorders often improves the

sleep impairment, and medications used to treat neuropsychiatric disorders may also be used as primary treatments for sleep disorders. The most promising aspect of this relationship was

explicitly postulated 30 years ago for mood disorders: not only is sleep disturbance a phenotypic feature of many neuropsychiatric illnesses, but it may in fact predispose, contribute to,

and dare we say it, cause them [1, 2]. The Epidemiologic Catchment Area study was the first high-profile data demonstrating that insomnia was a strong predictor of incident mood disorders,

suggesting that sleeplessness was thus “an opportunity for prevention”. This type of “bidirectional” relationship with insomnia has been demonstrated (although not equivocally) over the last

30 years for a number of neuropsychiatric disorders, including bipolar disorder [3], anxiety disorders [4], PTSD [5], substance use disorders [6], and Alzheimer’s disease [7]. Sleep

disturbance has also been established as a risk for transdiagnostic symptoms such as suicidality and pain [8, 9]. Further, circadian rhythm dysregulation (independent of sleep disturbance)

may be a risk for neuropsychiatric illness, including bipolar disorder, neurodegenerative disorders, and schizophrenia [10, 11]. Many of the papers in the current issue of

Neuropsychopharmacology Reviews discuss the bidirectional relationship of sleep disturbance/circadian rhythms and neuropsychiatric illness, and their potential underlying neurobiological

mechanisms. As recognition of the complex role that sleep disturbance plays in psychiatric illness, DSM-5 mitigated the nearly impossible task for clinicians of determining whether insomnia

was caused by psychiatric illness or vice-versa. This continued the evolution of previous DSM editions in eliminating distinctions between primary vs secondary, and subsequently primary vs

comorbid, insomnia; instead insomnia diagnosis in DSM-5 is primarily based on symptom features, frequency, and duration. As a result, it encourages independent treatment of insomnia, as well

as facilitating further research into the role of sleep disturbance in the etiology and natural history of psychiatric illness. Multiple approaches to the analysis of sleep function exist,

many of which are addressed in this special issue. Whereas the EEG has been the standard method to determine differences in brain activity during vigilance states, fMRI, DTI, and other

imaging methods have added information about the role of specific networks in sleep/wake dysfunction and hyperarousal conditions. Further, multimodal and longitudinal recordings of

physiological parameters using wearables will add precision to the characterization of the arousal dysfunctions [12]. Significant advances in systems neuroscience have generated a much more

detailed picture of the neuronal circuitry underlying sleep/wake control (reviewed by Jones et al. in this issue), and hyperarousal [13, 14]. For instance, Eban-Rothschild et al. [15]

described a causal role of mesocorticolimbic dopaminergic activity in sleep and wakefulness. Alterations of dopaminergic neurons have long been associated with hyperarousal, PTSD [14],

autism [16], and alcoholism and drug abuse [17]. Also, advances in molecular genetics of memory [18], cognitive performance, and circadian oscillations have dramatically increased our

understanding of such connections [19, 20]. Hypocretin/orexin release in the brain correlates with accumulation of beta amyloid peptides, providing a molecular connection between sleep

circuits and sleep dysfunction in Alzheimer’s disease [21]. In addition to AD, sleep disruption accompanies the progression of several neurodegenerative disorders including Parkinson’s and

newly described autoimmune disorders [22, 23]. Genetic variants associated with the neuronal activity associated with these circuits will likely predict risk for neuropsychiatric disorders.

Together, this special issue highlights the role of sleep in maintaining a healthy brain. We expect that a comprehensive characterization of sleep and arousal circuits will increase the

arsenal of methods to precisely increase sleep quality, thereby increasing quality of life in neuropsychiatric patients. FUNDING AND DISCLOSURE The authors declare no competing interests.

REFERENCES * Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987;144:201–4. Article  CAS  Google Scholar  * Ford DE,

Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 1989;262:1479–84. Article  CAS  Google Scholar  * Harvey AG. Sleep and

circadian functioning: critical mechanisms in the mood disorders? Annu Rev Clin Psychol 2011;7:297–319. Article  Google Scholar  * Chung KH, Li CY, Kuo SY, Sithole T, Liu WW, Chung MH. Risk

of psychiatric disorders in patients with chronic insomnia and sedative-hypnotic prescription: a nationwide population-based follow-up study. J Clin Sleep Med 2015;11:543–51. Article  Google

Scholar  * Wang HE, Campbell-Sills L, Kessler RC, Sun X, Heeringa SG, Nock MK, et al. Pre-deployment insomnia is associated with post-deployment post-traumatic stress disorder and suicidal

ideation in US Army soldiers. Sleep. 2019;42. * Dolsen MR, Harvey AG. Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse

among adults seeking substance use treatment in the United States from 1991 to 1994. Addiction 2017;112:1104–11. Article  Google Scholar  * Irwin MR, Vitiello MV. Implications of sleep

disturbance and inflammation for Alzheimer’s disease dementia. Lancet Neurol 2019;18:296–306. Article  CAS  Google Scholar  * Pigeon WR, Pinquart M, Conner K. Meta-analysis of sleep

disturbance and suicidal thoughts and behaviors. J Clin Psychiatry. 2012;73:e1160–7. Article  Google Scholar  * Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update

and a path forward. J Pain 2013;14:1539–52. Article  Google Scholar  * Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases.

Lancet Neurol 2019;18:307–18. Article  Google Scholar  * Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry

2012;200:308–16. Article  Google Scholar  * Goldstein-Piekarski AN, Williams LM. New technologies for precision psychiatry. Neuropsychopharmacology. 2019. * Jones BE. Arousal and sleep

circuits. Neuropsychopharmacology. 2019. Article  Google Scholar  * Neylan TC. Sleep disturbance across anxiety-related disorders: an updated review and a discussion about the

transdiagnostic role of arousal and threat. Neuropsychopharmacology. 2019. * Eban-Rothschild A, Rothschild G, Giardino WJ, Jones JR, de Lecea L. VTA dopaminergic neurons regulate

ethologically relevant sleep-wake behaviors. Nat Neurosci 2016;19:1356–66. Article  CAS  Google Scholar  * Missig G, McDougle CJ, Carlezon WA, Jr. Sleep as a translationally-relevant

endpoint in studies of autism spectrum disorder (ASD). Neuropsychopharmacology. 2019. * Koob GF, Colrain IM. Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework.

Neuropsychopharmacology. 2019. * Born J. Neurochemical mechanisms for memory processing during sleep – basic findings in humans and neuropsychiatric implications. Neuropsychopharmacology.

2019. * Hudson AN, Van Dongen HPA, Honn KA. Sleep deprivation, vigilant attention, and brain function: a review. Neuropsychopharmacology. 2019. * Ashbrook L, Krystal A, Fu YH, Ptacek LJ.

Genetics of the human circadian clock and sleep homeostat. Neuropsychopharmacology. 2019. * Holtzman DM. Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid,

tau, and other factors. Neuropsychopharmacology. 2019. * Stefani A, Hogl B. Sleep in Parkinson’s disease. Neuropsychopharmacology. 2019. * Iranzo A. Sleep and neurological autoimmune

diseases. Neuropsychopharmacology. 2019. Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Professor of Psychiatry, Harvard Medical School, Departments of Psychiatry and

Neurology, Massachusetts General Hospital, Boston, USA John W. Winkelman * Professor of Psychiatry and Behavioral Sciences. Dept. of Psychiatry and Behavioral Sciences, Stanford University

Medical School, Stanford, USA Luis de Lecea Authors * John W. Winkelman View author publications You can also search for this author inPubMed Google Scholar * Luis de Lecea View author

publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHORS Correspondence to John W. Winkelman or Luis de Lecea. ADDITIONAL INFORMATION PUBLISHER’S NOTE

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE

THIS ARTICLE Winkelman, J.W., Lecea, L.d. Sleep and neuropsychiatric illness. _Neuropsychopharmacol._ 45, 1–2 (2020). https://doi.org/10.1038/s41386-019-0514-5 Download citation * Received:

27 August 2019 * Accepted: 27 August 2019 * Published: 05 September 2019 * Issue Date: January 2020 * DOI: https://doi.org/10.1038/s41386-019-0514-5 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative